Assesses the safety, tolerability, and preliminary efficacy of crenolanib, a PDGFR inhibitor, in targeting PDGFR-β-expressing CAFs in advanced or metastatic solid tumors, including lung cancer. This evidence concerns the gene PDGFRB and lung carcinoma.